Drugs / TIVUMECIRNON
TIVUMECIRNON
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03674567 | Sep 2018 → Dec 2024 | — | RAPT Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04894994 | Sep 2021 → Sep 2022 | melanoma | RAPT Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04768686 | May 2021 → Aug 2024 | gastric cancer | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-02-17 | Hanmi Pharmaceutical Company Limited | Results Hanmi Pharmaceutical Confirms ‘Complete Remission’ in Phase 1/2 Study of Its Innovative Selective CCR4 Antagonist hanmipharm.com ↗
During the event, the company disclosed the final results of the Phase 2 clinical trial of Tivumecirnon―an innovative gastric cancer drug―via a poster presentation. |
| 2025-02-17 | Hanmi Pharmaceutical Company Limited | Results 한미약품, CCR4 타깃 면역항암 혁신신약 임상 2상서 ‘완전관해’ 확인 hanmi.co.kr ↗
이번 학회에서 한미약품은 티부메시르논과 키트루다 병용요법이 엡스타인-바 바이러스(Epstein-Barr Virus, EBV) 양성 위암 환자에서 우수한 항종양 효과와 내약성을 확인한 연구 결과(임상 2상 단계 1)를 발표했다. |
| 2021-11-17 | Hanmi Pharmaceutical Company Limited | Results 한미약품, 세계 최초 CCR4 타깃 면역항암제 임상2상 미국학회서 발표 hanmi.co.kr ↗
사전에 항암 치료를 받고 올해 5월부터 임상에 참여한 EBV양성, HER2 음성 80세 위암 남자 환자에 FLX475와 키트루다를 병용 투여했을 때, 6주기 차에 간에 전이된 종양의 크기가 58% 감소하는 부분 반응(PR)이 확인됐다. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-17 | Hanmi Pharmaceutical Company Limited | Hanmi Pharmaceutical Confirms ‘Complete Remission’ in Phase 1/2 Study of Its Innovative Selective CCR4 Antagonist hanmipharm.com ↗ |
| 2025-02-17 | Hanmi Pharmaceutical Company Limited | 한미약품, CCR4 타깃 면역항암 혁신신약 임상 2상서 ‘완전관해’ 확인 hanmi.co.kr ↗ |
| 2021-11-17 | Hanmi Pharmaceutical Company Limited | 한미약품, 세계 최초 CCR4 타깃 면역항암제 임상2상 미국학회서 발표 hanmi.co.kr ↗ |
| 2020-09-15 | Hanmi Pharmaceutical Company Limited | <보도자료> 한미약품-MSD, ‘FLX475+키트루다’ 임상 협력 및 공급 협약 hanmi.co.kr ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIVUMECIRNON | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Known as | F003475 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Known as | FLX-3475 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Known as | FLX-475 BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Known as | FLX475 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04894994 ↗ |
| Known as | FP-0116 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Known as | TIVUMECIRNON BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314490 ↗ |
| Modality | Small molecule | — CHEMBL5314490 ↗ |
| Route | Oral | “FLX475 tablets orally” NCT04894994 ↗ |